[vc_row full_width=”stretch_row” css=”.vc_custom_1531732107238{background-color: #fcc118 !important;}”][vc_column]

[/vc_column][/vc_row][vc_row css=”.vc_custom_1531730959461{border-bottom-width: 1px !important;background-color: #f9fafb !important;border-bottom-color: #eef3f7 !important;border-bottom-style: solid !important;}”][vc_column css=”.vc_custom_1531891416301{margin-bottom: 0px !important;}”][bsfp-cryptocurrency style=”widget-6″ align=”auto” columns=”2″ scheme=”light” coins=”top-x-coins” coins-count=”8″ coins-selected=”” currency=”USD” title=”Cryptocurrencies” show_title=”0″ icon=”” heading_color=”” heading_style=”default” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ css=”.vc_custom_1531730265600{margin-bottom: 0px !important;}” custom-css-class=”” custom-id=””][/vc_column][/vc_row]

BMY Earnings: Everything you need to know about Bristol Myers’ Q4 results


Bristol Myers Squibb (NYSE: BMY) on Thursday announced results for the fourth quarter of 2022, reporting lower earnings and revenues.

The pharma company reported revenues of $11.4 billion for the fourth quarter, down 5% from the same period a year ago. Net earnings attributable to the company were $2.02 billion, or $0.95 per share, compared to $2.37 billion, or $1.07 per share a year earlier. Adjusted earnings edged down by 1% to $1.82 per share.

“With a younger and more diversified portfolio, promising mid-to-late-stage registrational assets, and a deep early-stage pipeline, I am confident that the company is well-positioned for multiple waves of innovation that will support long-term growth,” said the company’s CEO Giovanni Caforio.

Prior Performance

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More